Phase 2 Study of NOV-002 in Low and Intermediate-1 Risk Myelodysplastic Syndrome
The Study Drug:
NOV-002 is a type of blood cell production stimulating drug. NOV-002 is believed to
stimulate the bone marrow to increase production of mature cells in the bloodstream,
including red and white blood cells and platelets.
Signing this consent form does not mean that you will be able to take part in this study.
You will have "screening tests" to help the doctor decide if you are eligible to take part
in this study. The following tests and procedures will be performed:
- Your medical history will be recorded.
- You will be asked about any drugs you have taken or may be taking.
- You will have a physical exam, including measurement of your weight and vital signs
(blood pressure, temperature, breathing rate, and heart rate).
- Urine will be collected for routine tests.
- Blood (about 7 teaspoons) will be drawn for routine tests and to check for HIV and
hepatitis B and C.
- If you have not had a bone marrow aspiration in the month before the screening tests,
one will be performed to check the status of the disease. To collect a bone marrow
aspirate, an area of the hip is numbed with anesthetic, and a small amount of bone
marrow is withdrawn through a large needle.
- Women who are able to become pregnant will have a pregnancy test as part of the routine
blood or urine collection. To take part in this study, the pregnancy test must be
The study doctor will discuss the screening test results with you. If the screening tests
show that you are not eligible to take part in the study, you will not be enrolled. Other
treatment options will be discussed with you.
Study Drug Administration:
If you are found to be eligible to take part in this study, you will receive the study drug
NOV-002 through a needle under the skin 1 time each day while you are on study.
The study staff will teach you and/or a caregiver how to inject the study drug. The study
staff will also give you written copy of instructions on how and when you should inject the
You will be given diary cards to record when and where on your body you inject the study
drug, as well as any side effects that may occur. If you miss a dose of study drug, you
should note that on your diary card and take the study drug the next day as scheduled. You
should not take a double, "make-up" dose at that time.
You must store the study drug in a refrigerator and out of the reach of children. You will
be asked to bring all leftover study drug to each study visit.
- You will have study visits 1 time each week during Weeks 1-8 and 1 time each month
during Months 3-12. At these visits, the following tests and procedures will be
- You will be asked about any drugs you have taken or may be taking and about any side
effects you may have experienced.
- Your vital signs will be measured.
- Blood (about 5 teaspoons) will be drawn for routine tests.
- You will have a physical exam 1 time each month while you are on study.
- You will have a bone marrow aspiration every 3 months while you are on study to check
the status of the disease.
Length of Study:
You will take the study drug for up to 12 months. You will be taken off study if you have
intolerable side effects, if the disease gets worse, or if the doctor thinks it is in your
After you have finished taking the study drug for any reason, the following procedures will
be performed for about 12 months, but will be stopped if you start receiving a different
treatment or if the disease gets worse:
Blood (about 5 teaspoons) will be drawn for routine tests 1 time each month. You will have a
bone marrow aspiration every 3 months.
This is an investigational study. NOV-002 is not FDA approved or commercially available.
At this time, it is only being used in research.
Up to 40 patients will take part in this study. All will be enrolled at M. D. Anderson.
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Overall Response (OR)
Baseline to measured progressive disease (anticipated treatment period 3 -12 months)
Gautam Borthakur, MBBS
UT MD Anderson Cancer Center
United States: Institutional Review Board